[go: up one dir, main page]

CU20150163A7 - DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET - Google Patents

DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET

Info

Publication number
CU20150163A7
CU20150163A7 CUP2015000163A CU20150163A CU20150163A7 CU 20150163 A7 CU20150163 A7 CU 20150163A7 CU P2015000163 A CUP2015000163 A CU P2015000163A CU 20150163 A CU20150163 A CU 20150163A CU 20150163 A7 CU20150163 A7 CU 20150163A7
Authority
CU
Cuba
Prior art keywords
derivatives
active
dihidropirrolo
heteroaril
fenil
Prior art date
Application number
CUP2015000163A
Other languages
English (en)
Other versions
CU24350B1 (es
Inventor
Jutta Blank
Vincent Bordas
Simona Cotesta
Vito Guagnano
Heinrich Rueeger
Andrea Vaupel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150163A7 publication Critical patent/CU20150163A7/es
Publication of CU24350B1 publication Critical patent/CU24350B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) (ESPACIO PARA LA FÓRMULA) o una sal farmacéuticamente aceptable del mismo, que corresponde con derivados de 5 heteroaril-4-fenil-4,5-dihidropirrolo (3,4-c)pirazol-6-ona activos como inhibidores de BET, que tienen potencial terapéutico en varias condiciones o enfermedades humanas como cáncer; composiciones farmacéuticas de los mismos y combinaciones con agentes farmacológicamente activos.
CUP2015000163A 2013-05-27 2014-05-26 DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET CU24350B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13169364 2013-05-27
EP13177673 2013-07-23
PCT/IB2014/061717 WO2014191896A1 (en) 2013-05-27 2014-05-26 Pyrazolopyrrolidine derivatives and their use in the treatment of disease

Publications (2)

Publication Number Publication Date
CU20150163A7 true CU20150163A7 (es) 2016-05-30
CU24350B1 CU24350B1 (es) 2018-06-05

Family

ID=50979827

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000163A CU24350B1 (es) 2013-05-27 2014-05-26 DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET

Country Status (37)

Country Link
US (2) US8975417B2 (es)
EP (1) EP3004110B1 (es)
JP (1) JP6181862B2 (es)
KR (1) KR20160012196A (es)
CN (1) CN105408335B (es)
AU (1) AU2014272776C1 (es)
BR (1) BR112015029512A8 (es)
CA (1) CA2913223A1 (es)
CL (1) CL2015003395A1 (es)
CR (1) CR20150628A (es)
CU (1) CU24350B1 (es)
CY (1) CY1119490T1 (es)
DK (1) DK3004110T3 (es)
EA (1) EA029515B1 (es)
EC (1) ECSP15053445A (es)
ES (1) ES2651843T3 (es)
HK (1) HK1216251A1 (es)
HR (1) HRP20171613T1 (es)
HU (1) HUE036674T2 (es)
IL (1) IL242610A0 (es)
LT (1) LT3004110T (es)
ME (1) ME02906B (es)
MX (1) MX364205B (es)
NO (1) NO3004110T3 (es)
PE (1) PE20160005A1 (es)
PH (2) PH12015502628B1 (es)
PL (1) PL3004110T3 (es)
PT (1) PT3004110T (es)
RS (1) RS56522B1 (es)
SG (1) SG11201509474SA (es)
SI (1) SI3004110T1 (es)
SV (1) SV2015005115A (es)
TN (1) TN2015000505A1 (es)
UA (1) UA116017C2 (es)
UY (1) UY35586A (es)
WO (1) WO2014191896A1 (es)
ZA (1) ZA201508259B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3004108B1 (en) * 2013-05-28 2017-10-18 Novartis AG Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
LT3290407T (lt) 2013-10-18 2020-04-10 Celgene Quanticel Research, Inc Bromodomeno inhibitoriai
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
PT3674302T (pt) 2014-04-23 2023-05-10 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores das proteínas bet
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017127930A1 (en) * 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
CA3013988A1 (en) 2016-02-15 2017-08-24 Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
TW201803594A (zh) * 2016-06-09 2018-02-01 達納-法伯癌症協會 Hdac抑制劑與bet抑制劑之使用方法及醫藥組合
KR20240033293A (ko) 2016-06-20 2024-03-12 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
JP7032814B2 (ja) 2016-08-31 2022-03-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド オキソピコリンアミド誘導体、その製造方法およびその医薬用途
WO2018087401A2 (en) 2016-11-14 2018-05-17 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
PH12022550079A1 (en) * 2019-07-12 2023-04-12 Scenic Immunology B V N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme
WO2021065980A1 (ja) 2019-09-30 2021-04-08 協和キリン株式会社 Ｂｅｔ分解剤
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117157296A (zh) * 2021-01-21 2023-12-01 首都医科大学附属北京天坛医院 Fpr1的调节剂及其使用方法
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN118368986A (zh) 2021-12-17 2024-07-19 先正达农作物保护股份公司 杀微生物的吡唑衍生物
AU2023279223A1 (en) 2022-05-30 2024-12-12 AdoRx Therapeutics Limited Cd73 inhibitor compounds
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202435758A (zh) 2023-01-27 2024-09-16 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202434112A (zh) 2023-02-01 2024-09-01 瑞士商先正達農作物保護股份公司 殺真菌組成物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024256438A1 (en) 2023-06-14 2024-12-19 Syngenta Crop Protection Ag Fungicidal compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
BR0113176A (pt) 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
PL221339B1 (pl) * 2001-05-24 2016-03-31 Lilly Co Eli Nowe pochodne pirolu jako środki farmaceutyczne
BR0215157A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
AU2003235504A1 (en) 2002-05-13 2003-11-11 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
CA2589830A1 (en) 2005-01-05 2006-07-13 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
AU2006326063B2 (en) 2005-12-12 2012-07-19 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
WO2007096334A1 (en) 2006-02-24 2007-08-30 Pfizer Italia Srl Pyrrolopyrrolones active as kinase inhibitors
WO2008034039A2 (en) 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
KR20100016076A (ko) 2007-03-30 2010-02-12 시오노기 앤드 컴파니, 리미티드 신규 피롤리논 유도체 및 그것을 함유하는 의약 조성물
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010035727A1 (ja) 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
US20120208204A1 (en) 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20130252331A1 (en) * 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
GB2492950A (en) 2011-07-11 2013-01-23 Cambridge Consultants Measuring a luminescent property of a sample using a dual-modulated excitation beam
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物

Also Published As

Publication number Publication date
UY35586A (es) 2014-12-31
HK1216251A1 (zh) 2016-10-28
ME02906B (me) 2018-04-20
PH12015502628A1 (en) 2016-03-07
CU24350B1 (es) 2018-06-05
CA2913223A1 (en) 2014-12-04
JP6181862B2 (ja) 2017-08-16
MX2015016416A (es) 2016-03-03
ZA201508259B (en) 2017-01-25
BR112015029512A2 (pt) 2017-07-25
US20160095843A1 (en) 2016-04-07
CN105408335B (zh) 2017-11-17
BR112015029512A8 (pt) 2019-12-17
IL242610A0 (en) 2016-02-01
KR20160012196A (ko) 2016-02-02
CN105408335A (zh) 2016-03-16
AU2014272776C1 (en) 2017-06-01
RS56522B1 (sr) 2018-02-28
SI3004110T1 (sl) 2017-11-30
PT3004110T (pt) 2017-11-08
EA029515B1 (ru) 2018-04-30
US8975417B2 (en) 2015-03-10
AU2014272776A1 (en) 2015-12-03
PE20160005A1 (es) 2016-01-21
PL3004110T3 (pl) 2017-12-29
MX364205B (es) 2019-04-16
AU2014272776B2 (en) 2016-11-10
PH12018501807A1 (en) 2019-03-25
HRP20171613T1 (hr) 2017-12-01
ECSP15053445A (es) 2017-10-31
CL2015003395A1 (es) 2016-05-20
HUE036674T2 (hu) 2018-07-30
JP2016520117A (ja) 2016-07-11
PH12015502628B1 (en) 2016-03-07
NO3004110T3 (es) 2017-12-23
DK3004110T3 (da) 2017-11-06
UA116017C2 (uk) 2018-01-25
WO2014191896A1 (en) 2014-12-04
EP3004110A1 (en) 2016-04-13
EP3004110B1 (en) 2017-07-26
SG11201509474SA (en) 2015-12-30
TN2015000505A1 (en) 2017-04-06
LT3004110T (lt) 2017-11-10
EA201592250A1 (ru) 2016-05-31
CR20150628A (es) 2016-01-29
US20140349990A1 (en) 2014-11-27
ES2651843T3 (es) 2018-01-30
SV2015005115A (es) 2018-04-04
CY1119490T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
PH12016500024A1 (en) Bromodomain inhibitor
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
BR112016000561A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX360495B (es) Derivados deuterados de ruxolitinib.
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
CO7141411A2 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
UY36207A (es) Inhibidores de la syk
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
UY35209A (es) Compuestos tricíclicos
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
UY35211A (es) Compuestos tricíclicos
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.